Clinical trial
Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)
NCT00073177 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00073177 |
|---|---|
| Title | Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012) |
| Official title | A 24 Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Roflumilast (250 mcg or 500 mcg) Daily in Patients With Asthma |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Roflumilast |
| Enrollment | 819 |
| Start date | Nov 1, 2003 |
| First posted | Nov 19, 2003 |
| Last update posted | Oct 25, 2016 |
| Countries | Argentina, Colombia, Mexico, Peru, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: